Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536492 | 0.88 | HSD11B1 (0.35) | AURKAGRK6MDM2 | |
| SCHEMBL23776206 | 0.82 | OPRD1 (0.37) | ESR1ESR2 | |
| SCHEMBL21245968 | 0.74 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL23503056 | 0.72 | AR (0.32) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16311933 | 0.71 | ALDH1A1 (0.41) | AURKAGRK6ESR1ESR2SCN10A | |
| SCHEMBL15316713 | 0.70 | NOS3 (0.34) | ESR1KDM4EKCNH2 | |
| SCHEMBL2737290 | 0.70 | ALDH1A1 (0.46) | SCN10AKDM4EALDH1A1L3MBTL1GRM5 | |
| SCHEMBL19919593 | 0.69 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL21024658 | 0.68 | KDM4E (0.40) | AURKAGRK6ESR1ESR2SCN10A | |
| SCHEMBL20133641 | 0.68 | KDM4E (0.31) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | AURKA 3062/4885GRK6 3578/4885ESR1 4465/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | AURKA 3062/4885GRK6 3578/4885ESR1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.